Revision of PRECAUTIONS

Brimonidine tartrate
Brimonidine tartrate/brinzolamide
Ripasudil hydrochloride hydrate/brimonidine tartrate

June 11, 2024

Therapeutic category
Agents for ophthalmic use

Non-proprietary name
Brimonidine tartrate
Brimonidine tartrate/brinzolamide
Ripasudil hydrochloride hydrate/brimonidine tartrate

Safety measure
PRECAUTIONS should be revised.
<table>
<thead>
<tr>
<th>Current</th>
<th>Revision</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>8. IMPORTANT PRECAUTIONS</strong>&lt;br&gt;(N/A)</td>
<td><strong>8. IMPORTANT PRECAUTIONS</strong>&lt;br&gt;Corneal opacity with neovascularisation, etc. may occur following administration of this drug. Patients should consult their doctor periodically, and they should be carefully monitored. In addition, they should be adequately instructed to seek medical attention immediately if they have any subjective symptoms such as hyperaemia, reduced visual acuity, or blurred vision.</td>
</tr>
<tr>
<td><strong>11. ADVERSE REACTIONS</strong>&lt;br&gt;(N/A)</td>
<td><strong>11. ADVERSE REACTIONS</strong>&lt;br&gt;11.1 Clinically Significant Adverse Reactions&lt;br&gt;Corneal opacity</td>
</tr>
</tbody>
</table>


Note: Brimonidine tartrate is designated as a drug requiring preparation of a Drug Guide for Patients.

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.